Provider status gets all the headlines. The Main Street Pharmacy Access Act fills the advocacy newsletters. But a quieter, more structural regulatory reform gaining momentum in state legislatures right now could ultimately do more for individual pharmacist autonomy than any federal bill. Most pharmacists have never heard of it.
It is called the Standard of Care model. And Pharmacy Times published one of the most compelling arguments this week for why it should be the profession’s single top legislative priority heading into 2027.
The Problem with the Current Framework
Nearly every state regulates pharmacy practice through prescriptive, rules-based pharmacy practice acts. These documents specify exactly what a pharmacist can and cannot do, often written years or decades before the clinical landscape they now govern. The laws were designed for a profession of dispensers. They are being applied to a profession of clinicians. The gap between the two is where pharmacists get stuck.
The rules-based model has a structural failure that compounds over time: as clinical science advances, as new drug classes arrive, as new care coordination models emerge, as technology changes what is operationally possible, the pharmacy practice act remains static until a legislature convenes, a bill passes, and a governor signs. The physician adapts their practice as medicine evolves. The pharmacist files a legislative request and waits.
That structural lag is not a minor inconvenience. It is the primary reason that pharmacists’ clinical capabilities consistently outpace the legal authority to exercise them. The pharmacist who can interpret a CGM trace, recommend a GLP-1 dose adjustment, identify a MASLD patient through FIB-4 calculation, and coordinate a referral to nephrology has the clinical training to do all of those things. Whether they have the legal authority depends on whether their state legislature has gotten around to adding each item to the permitted list.
What the Standard of Care Model Actually Means
The Standard of Care model replaces the rigid, rules-based framework with a principle-based one. Instead of a list of permitted actions, the law holds a pharmacist to the standard expected of a reasonable and prudent pharmacist with similar qualifications in a similar situation.
This is the same framework that governs physician practice across every state in the country. It is the same framework governing nursing practice. When a physician encounters a clinical situation that is not explicitly covered by a statute, they apply professional judgment calibrated to the standard of care for their specialty and their patient population. When they deviate from that standard, they face liability. When they practice within it, they practice with autonomy.
The Standard of Care model extends that same professional accountability structure to pharmacy. Pharmacists practicing under it can exercise clinical authority based on their education, training, and experience, provided their decisions align with widely accepted professional standards and guidelines, including those from ASHP, ADA, APhA, CPIC, and the disease-specific guidelines of other professional medical societies. The accountability is professional and legal, not statutory. The permitted list is replaced by the standard of practice.
One important clarification the Standard of Care model’s advocates consistently make: SOC does not automatically equal full practice authority. Full independent prescribing authority, the ability to initiate, modify, and discontinue therapy without any prescriber involvement, requires additional legislative steps in most state frameworks. What SOC does is create the regulatory foundation from which full practice authority can be built, and it removes the structural barrier that has kept pharmacy’s clinical evolution artificially constrained by laws written for a different era.
Idaho: The Proof of Concept Every Pharmacist Needs to Know
Idaho provides the clearest real-world example of what Standard of Care pharmacy regulation produces in practice.
Idaho pharmacists currently have full authority to independently prescribe medications, administer vaccines, order and interpret laboratory tests, and adapt prescriptions. Idaho pharmacists may independently prescribe treatments for minor ailments such as influenza, urinary tract infections, and several other conditions without detailed regulatory constraints on how they exercise that judgment. They are held to the standard of practice among peers with comparable education and training, not to a checklist of permitted activities.
The expansion of pharmacist scope did not come at the expense of patient safety outcomes. Idaho’s patient safety record in pharmacy practice has not generated documented adverse event signals attributable to the expanded scope framework. What it has generated is a practice environment where pharmacists can actually practice at the level their clinical training prepares them for.
A pharmacist in Idaho who sees a patient presenting with classic UTI symptoms can assess, prescribe a first-line antibiotic, and counsel on expectations and follow-up without routing through a physician. A pharmacist in most other states cannot, not because their training is different, but because their state’s pharmacy practice act hasn’t gotten around to adding that specific service to the permitted list.
The Idaho model is not a regional anomaly. It is a regulatory precedent. And the path Idaho took, adopting a Standard of Care framework that grounds pharmacist practice in professional judgment rather than statutory enumeration, is available to any state willing to rewrite its pharmacy practice act around the same principle.
Why This Is Bigger Than Provider Status Alone
Provider status, as defined by the Main Street Pharmacy Access Act HR 3164, creates Medicare billing rights for specific, enumerated services in states that already authorize those services. This newsletter covered the committee passage of that bill in May and has tracked its progress since. Provider status is critically important. The billing rights it creates will generate meaningful revenue for clinical pharmacist services. Every pharmacist in the country should be advocating for its passage.
But provider status still operates within a rules-based framework. It adds specific items to the list of things pharmacists can bill for. Each new service category, each new billing code, each new clinical function still requires legislative or regulatory action to enumerate. The structure that requires that enumeration remains intact.
The Standard of Care model is categorically different. It doesn’t add items to the permitted list. It eliminates the list-based structure entirely and replaces it with the same professional judgment standard that allows a physician to adapt their practice as medicine evolves without waiting for the legislature to update a statute each time the science advances.
Consider what this means for the clinical innovations this newsletter has documented throughout 2026. A pharmacist in an Idaho-model state who sees the new ACTIV-6 metformin data for long COVID prevention and wants to build a proactive counseling protocol for COVID-positive patients on metformin doesn’t need to wait for their state to add “long COVID prevention counseling” to the practice act. Their professional judgment, grounded in published evidence and professional society guidance, is the regulatory authority. A pharmacist in a rules-based state may need to wait for a legislative cycle before they can formally offer that service.
The clinical world moves faster than legislative calendars. The Standard of Care model closes that gap structurally.
The JCPP Update That Signals the Profession’s Own Direction
The Joint Commission of Pharmacy Practitioners updated its Pharmacists’ Patient Care Process in May 2026 to explicitly reflect this direction. The updated PPCP states that pharmacists provide a wide array of patient care services aligned with standard of care, consistent with scope of practice, and facilitated by collaborative practice agreements, statewide protocols, standing orders, and independent prescribing authority.
That language is significant because it is not advocacy. It is the profession’s own governance framework describing how pharmacist clinical practice is already structured. The JCPP, which represents the major national pharmacy organizations including APhA, ASHP, ACCP, NCPA, and NASPA, is describing pharmacist practice as standard-of-care-based, not rules-list-based.
The state laws governing practice in most states have not caught up with the profession’s own self-description. The Standard of Care legislative campaign is the effort to close that gap, making the statutory framework match the professional framework the JCPP already describes.
The States Leading Right Now and the Pathway Forward
Beyond Idaho, California’s Board of Pharmacy has been actively evaluating a Standard of Care framework. The California Pharmacists Association’s advocacy campaign for SOC reform has produced the clearest public roadmap for how to move this legislation through a complex state regulatory environment.
The legislative sequence in states that have successfully moved toward SOC-based frameworks follows a consistent pattern. The state pharmacy association defines the SOC model in stakeholder education materials accessible to both pharmacists and legislators. A legislative champion is identified, typically a pharmacist, a physician who practices in collaborative care settings, or a rural health advocate who understands the access argument. The bill is introduced with specific language replacing the enumerated practice list with the standard-of-practice framework. The state board of pharmacy develops implementing regulations that define the professional standards against which pharmacist judgment will be evaluated. A rulemaking process finalizes those standards with input from both pharmacy and medical professional organizations.
That sequence takes two to four legislative years in states where the pharmacy association has not yet developed the political infrastructure to move it faster. Idaho’s SOC framework did not arrive quickly. It was built over years of consistent advocacy by pharmacists who understood that the practice act was the fundamental constraint and stayed focused on it.
The states where SOC reform is most likely to advance in 2027 are those where pharmacy associations have already introduced concept legislation or begun stakeholder engagement with state boards of pharmacy. Knowing whether your state is in that category requires calling your state association and asking directly.
The Practical Difference in Day-to-Day Practice
Abstract regulatory arguments have limited motivating power. The concrete clinical scenarios are clearer.
A pharmacist practicing under a rules-based framework encounters a patient with a straightforward Streptococcus pyogenes upper respiratory infection on a Monday morning. Their state has not yet passed a pharmacist test-and-treat statute for strep. They perform a rapid strep test, confirm the result, and recommend the patient call their physician for an antibiotic prescription. The patient, who works two jobs and cannot easily access a physician appointment that day, leaves without treatment. This is a care access failure. The pharmacist had the clinical knowledge to treat it. The law prevented them.
A pharmacist practicing under an Idaho-model Standard of Care framework encounters the same patient. They perform the test, confirm the result, apply professional judgment calibrated to the standard of care for strep pharyngitis treatment, and prescribe amoxicillin. The patient receives appropriate treatment that day. No access failure occurs.
The same pharmacist, the same clinical training, the same test, the same patient, the same diagnosis. Different regulatory framework. Different patient outcome.
Multiply that scenario across UTI, uncomplicated skin infections, influenza treatment, hormonal contraception, smoking cessation, and the growing range of clinical functions pharmacists can perform with their current training. The daily clinical impact of the regulatory framework choice is not marginal. It is the difference between pharmacy functioning as a clinical access point and pharmacy functioning as a referral intermediary.
Your Action This Week
Look up your state’s current pharmacy practice act definition of “practice of pharmacy” at your state board of pharmacy’s website. Read the specific language used to define what a pharmacist is authorized to do. Then ask one question: is this definition broad enough to encompass what you do as a clinician, or is it still written around the pharmacist-as-dispenser model?
If the definition is still built around dispensing, compounding, and a list of enumerated services, your state is operating under a framework that was designed before the clinical role you occupy today was fully envisioned.
Contact your state pharmacy association this week and ask two specific questions. Is Standard of Care regulatory reform on the 2027 legislative agenda? If not, what would it take to put it there?
The pharmacists who bring this conversation to their associations are the ones who determine whether their state moves toward an Idaho model or stays in the checklist era for another decade. The profession’s clinical future is being written in state capitals right now. It belongs to the pharmacists who show up.
Provider status will open the billing window. Standard of Care reform will open the door.
Sources: Pharmacy Times (Standard of Care: The Regulatory Reform That Could Transform Pharmacy Practice, August 2026), Idaho State Board of Pharmacy (Idaho Pharmacy Practice Act: Scope of Pharmacist Practice and Independent Prescribing Authority), American Pharmacists Association (Pharmacists’ Patient Care Process, Updated JCPP Framework, May 2026), Joint Commission of Pharmacy Practitioners (PPCP Update, May 2026), California Pharmacists Association (Standard of Care Advocacy Campaign Overview, 2026), NASPA (Pharmacist Scope of Practice by State: Current Framework Summary, 2026), Drug Topics (Main Street Pharmacy Access Act Committee Passage Coverage, May 2026), ASHP Practice Advancement Initiative 2030 (Recommendations for Expanded Pharmacist Scope and Professional Practice Authority)
